Dry AMD Drugs Linked to Retinal Nerve Fiber Layer Thickening

Complement inhibitors used to treat geographic atrophy (GA), a form of dry age-related macular degeneration (AMD), have been associated with thickening of the retinal nerve fiber layer (RNFL). This finding was reported at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle.

The study, which analyzed optical coherence tomography (OCT) scans from patients treated with complement inhibitors, observed an increase in RNFL thickness. Researchers are investigating whether this thickening is a beneficial response, potentially indicating improved retinal health, or a pathological change that could lead to vision problems. The implications of this finding are significant for the ongoing development and clinical application of these therapies.

Geographic atrophy is a leading cause of irreversible vision loss in individuals over 50. Complement inhibitors target the complement cascade, a part of the immune system implicated in the progression of GA. While these drugs have shown promise in slowing disease progression, the newly identified association with RNFL thickening warrants further investigation to understand its long-term effects on visual function and overall retinal health. The study did not specify the exact complement inhibitors used but indicated they are FDA-approved treatments for GA.